Healthcare Services company Suven Life Sciences announced Q1FY26 results Revenue: Rs 24.67 million compared to Rs 50.14 million during Q1FY25. PAT: Rs -515.17 million compared to Rs -280.40 million during Q1FY25. EPS: Rs -2.36 for Q1FY26. Result PDF
Healthcare Services company Suven Life Sciences announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue: Rs 26.90 million compared to Rs 66.68 million during Q4FY24. PAT: Rs -439.45 million compared to Rs -265.41 million during Q4FY24. EPS: Rs -2.02 compared to Rs -1.22 million during Q4FY24. FY25 Financial Highlights: Revenue: Rs 175.53 million compared to Rs 328.23 million during FY24. PAT: Rs -1,607.45 million compared to Rs -1,050.76 million during FY24. EPS: Rs -7.37 compared to Rs -4.82 million during FY24. Result PDF
Healthcare Services company Suven Life Sciences announced Q3FY25 results Revenue: Rs 32.40 million compared to Rs 85.16 million during Q3FY24. PAT: Rs -391.17 million compared to Rs -417.65 million during Q3FY24. EPS: Rs -1.79 for Q3FY25. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q1FY26. SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Preparing to start Phase 2B clinical study in Q1FY26. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition in MDD during FY26. SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule. Result PDF
Pharmaceuticals company Suven Life Sciences announced Q2FY25 results Revenue: Rs 66.09 million, compared to Rs 82.01 million during Q2FY24. PAT/Loss: Rs -496.44 million, compared to Rs 126.80 million during Q2FY24. EPS: Rs -2.27, compared to Rs -0.58 during Q2FY24. Result PDF
Pharmaceuticals company Suven Life Sciences announced Q4FY24 & FY24 results: Financial Highlights: Suven Life Sciences reported a revenue of Rs 66.7 million in Q4FY24, showing a decline compared to the previous quarter's revenue of Rs 85.2 million. The company experienced a net loss after tax of Rs 265.4 million in Q4FY24, and a cumulative annual loss of Rs 1,050.8 million for the year FY24. Expenses Breakdown: R&D; and Operational expenses accounted for a significant portion of the total expenses, posting Rs 326.7 million for the quarter and Rs 1,397 million for the year. Depreciation and Amortisation costs were recorded at Rs 15.1 million for the quarter, while Finance costs were relatively low at Rs 0.3 million. Exceptional Items: An exceptional item included in the financials reflects an insurance claim received by the company, amounting to Rs 10.0 million. Comprehensive Income: The total comprehensive income for the quarter reflects a loss of Rs 267.4 million after factoring in other comprehensive income, which was a loss of Rs 2.0 million. Stock and Earnings per Share: The paid-up equity capital stood constant at Rs 218.1 million for the reported periods, while the Earnings Per Share (EPS) showed a loss of Rs 1.2 for the quarter and a loss of Rs 4.8 for the full year. Result PDF